modality · intermediate · partly written
Therapeutic monoclonal antibodies
A therapeutic antibody is a large engineered protein that binds one target outside the cell; the same modality gave a survival gain in breast cancer and a cytokine storm in six volunteers.
Also called: mAb, monoclonal antibody
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
The short version
An antibody drug is a large protein, roughly 148 kDa for trastuzumab, that binds the outside of one target. It cannot enter cells, so it works on receptors and signals. Trastuzumab lengthened survival; TGN1412 put six volunteers into cytokine storm. 1234
Reported, not yet replicated
What stays and what changes versus a small molecule more
Still a binder with a target, a dose and a safety question, but the binding surface is large and it acts on the human protein only. That specificity is the strength and the risk: a test species that lacks the target or its cell type gives no warning, as with CD28 in TGN1412. Trastuzumab shows the other side: selecting patients with a companion test makes a single-target antibody effective. 1234
Reported, not yet replicated
Two cases more
Trastuzumab: 469 women, median survival 25.1 versus 20.3 months, heart dysfunction 27 versus 8 percent with an anthracycline. TGN1412: six healthy volunteers, systemic inflammation in 90 minutes, critical illness in 12 to 16 hours, all survived. See both drug records. 23
Reported, not yet replicated
Limits of this record deep
Persistence, clearance and manufacturing were not researched here; no half-life or manufacturing source was opened. 1234
Our inference
What it is
A recombinant monoclonal antibody: a protein of about 148 kDa for trastuzumab, with a binding region for one target and a stem that engages immune cells. 1
Reported, not yet replicated
Intervenes at
Same as small molecule
Changes downstream
Delivery
Infused intravenously or injected under the skin; it acts on surface targets from the blood. The subcutaneous trastuzumab product needs hyaluronidase to disperse the dose. 1
Reported, not yet replicated
Persistence
One trastuzumab product is dosed every three weeks, which suggests a long residence; no half-life was read. 1
Our inference
Examples
Teach this
In one sentence
Therapeutic antibodies are large proteins that bind one target outside cells, and whether they help or harm depends on which target and whether the test animal carries it. 1234
Reported, not yet replicated
The five-minute version
An antibody works by binding a surface protein, and trastuzumab, which binds HER2, extended survival in HER2-positive breast cancer but carries a heart warning. TGN1412 bound CD28 on T cells and in 2006 caused a cytokine storm in all six volunteers, because the animals used for safety testing lacked CD28 on the relevant cells. The modality is the same; the target and the species biology differ. 1234
Reported, not yet replicated
What a listener will ask
Can an antibody reach targets inside cells?
The sources opened concern surface receptors; they do not cover intracellular targets.
Is it safer than a small molecule?
What is selected on?
The common wrong idea
Antibodies are so specific that they are safe if animal tests are clean.
Specificity is for the human target and cell type; TGN1412 passed animal tests because the animal cells lacked CD28. 1234
Reported, not yet replicated
The one citation to hand over: 4
Still open here
- How long does a typical antibody persist, and why? The label gives a three-weekly schedule for one product, but no half-life was read.
- Manufacturing and potency testing for antibodies was not researched here.
Linked from
Sources
- Genentech, Inc.. Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) prescribing information. FDA Drugs@FDA label, application 761106 (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Slamon DJ, et al.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (2001). paper; opened 2026-11-17 all records citing this
- Suntharalingam G, et al.. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028 (2006). paper; opened 2026-11-17 all records citing this
- Eastwood D, Findlay L, Poole S, et al.. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161:512-526 (2010). paper; opened 2026-11-17 all records citing this
- Final ESG report recommends new safeguards for first-in-man trials. PharmaTimes (2006). news, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/modalities/antibody.json